BNCT Cost in 2026: China vs Japan vs the United States
If you have been told that boron neutron capture therapy (BNCT) might be relevant to your case, you have probably already hit an obstacle: almost nobody publishes a price. That is not an accident. Clinical BNCT exists in only a handful of centres worldwide, and each country prices it differently — some publish rate cards, some quote only after reviewing a patient's records, and one major market has no clinical programme at all.
This guide compares the three places international patients ask about most: Japan (the most established programme), China (the newest, opened in early 2026) and the United States (which, as of 2026, has no clinical BNCT centre). Every figure below is attributed, and we say plainly which numbers come from published rate cards, which come from third-party reporting, and which can only be obtained from the hospital directly.
- Japan — published rates at the Southern Tohoku BNCT centre work out to roughly JPY 4.0–4.4 million per course (about US$25,000–28,000). Insured for Japanese residents; foreign patients are billed on a separate, unpublished basis.
- China — treatment began in Hainan in early 2026, using the same NeuCure® platform and the same boron-10 drug as Japan. Reported cost: roughly RMB 400,000–600,000 per course (about US$60,000–90,000).
- United States — no clinical BNCT facility in 2026. The first accelerator-based site is under construction at the University of Wisconsin–Madison for clinical trials.
- The thing that matters most — all three countries are working with the same generation of technology. The differences are about availability, experience and how transparently each centre prices — not about the physics.
Cost and access at a glance
| Japan | China (Hainan) | United States | |
|---|---|---|---|
| Clinically available | Yes — approved since 2020 | Yes — operating since early 2026 | No — first trial site under construction |
| Published cost | ~JPY 4.0–4.4m (~US$25,000–28,000) |
~RMB 400,000–600,000 (~US$60,000–90,000) |
Not applicable |
| Insured for residents | Yes, for approved indications | No — self-pay | Not applicable |
| Published international rate | No | No | Not applicable |
| Technology | NeuCure® + borofalan | NeuCure® + borofalan | AlphaBeam / nuBeam (trials only) |
| Approved indication | Locally advanced or recurrent head and neck cancer | Locally advanced or recurrent head and neck cancer | Not applicable |
Currency conversions use an indicative rate of about RMB 6.7 per US$1 (October 2026) and move with exchange rates. Ranges are indicative, compiled from the sources listed at the end of this page — they are not quotations. Only a written estimate from the treating centre, issued after reviewing your records, is a real price.
Why BNCT prices are so hard to find
Four things make this therapy unusually opaque on price, and understanding them makes the numbers below much easier to interpret.
- There is almost no installed base. Approvals are recent and equipment is scarce. Published market analyses put the number of BNCT systems approved for clinical use in the single digits worldwide, with most of them in Japan and one in China.
- The price is part equipment, part drug. In Japan the fee structure is explicitly split: a technology fee for the neutron irradiation, plus a drug fee charged by body weight. Two patients at the same hospital can therefore receive noticeably different bills.
- Centres refuse to quote without records. This is legitimate, not evasive. Eligibility depends on tumour type, size, prior radiotherapy and, critically, whether the tumour takes up enough boron to make treatment worthwhile — which is assessed with a dedicated boron-uptake PET scan. A price quoted before that assessment would be fiction.
- Some widely shared figures are not hospital prices. Figures circulating in medical-travel content are often agency packages (hospital fee plus translation, accommodation and escort services) or journalistic estimates. Mixing them with hospital rate cards produces the confusion you will find across most forums on this topic.
Japan: the most mature programme — and a pricing blind spot for foreigners
What Japan publishes
Japan approved accelerator-based BNCT in 2020, for locally advanced or recurrent head and neck cancer that cannot be surgically removed. The approval covers the NeuCure® system together with the boron-10 carrier drug borofalan (marketed as Steboronine®), and treatment is supported under national health insurance for residents.
The most-cited published rate structure comes from the Southern Tohoku BNCT Research Center, which sets out two components: a technology fee of approximately JPY 2.385 million, plus a drug fee charged at roughly JPY 444,000 per 18 kg of body weight. For most adults that lands above JPY 4 million for a course. Market reports covering 2025–2026 describe the insurance-bundled payment for an approved head and neck course as around JPY 2.7 million (roughly US$17,000), with the difference reflecting what the reimbursement covers rather than the undiscounted rate card.
The catch for international patients
Japan's national health insurance does not cover people who do not live there. International patients are billed on a separate, self-pay basis, and — this is the important part — no standard international rate has been published. Each centre handles foreign patients individually.
That gap is why Chinese-language medical-travel sites quote ranges as wide as US$600,000–800,000 for Japanese BNCT. Those are typically all-in agency packages covering hospital fees, interpretation, accommodation and accompaniment for the patient and a companion — a different product from the hospital's own treatment charge. If you are comparing Japan with anywhere else, ask every provider to separate the hospital fee from the service fee. Otherwise you are comparing a treatment price with a travel package.
China: the newest programme, and clearer numbers for visitors
Where it is, and who runs it
The Chinese programme is based at Panboron (Hainan) BNCT Hospital, inside the Bo'ao Lecheng International Medical Tourism Pilot Zone in Qionghai, Hainan Province. Lecheng is a specially regulated zone that allows certain drugs and devices already approved abroad to be used clinically in China before nationwide registration — which is how a BNCT service could open here ahead of the standard national pathway.
The hospital began trial operation in February 2026 and reported its first treatment — a recurrent tongue cancer case — in March 2026. It uses the NeuCure® system and the boron-10 drug borofalan: the same platform used clinically in Japan. Its approved indication is unresectable locally advanced or recurrent head and neck cancer, covering nasopharyngeal, sinonasal, laryngeal, oral, tongue, gingival and parotid cancers and related subtypes. The first phase is reported at around 40 beds.
What it costs
The programme's pricing has been reported at roughly RMB 400,000–600,000 per course. That is not a published rate card — the hospital issues quotations case by case — so treat it as a planning order of magnitude rather than a firm figure. The final number will depend on body weight (the boron drug is dosed by weight), the site and extent of disease, and the treatment plan the hospital settles on.
The Hainan programme is new. Its own independently published outcome data are still limited compared with the Japanese centres, which have treated patients for years. A lower price or a shorter wait does not by itself make a centre the right choice — what matters is how much experience the treating team has with your tumour type. We would rather you ask that question than assume newer or cheaper means better.
Why some international patients look at China
- Shorter queue. A newly opened centre has capacity to fill, whereas several established Japanese centres report waiting periods measured in months.
- The same platform. Same accelerator family, same boron drug — a comparable technical starting point, which is not always true across countries.
- Entry logistics. Hainan operates visa-free entry for citizens of a number of countries, and China has been widening visa-free and transit-free arrangements. Policies change and depend on your nationality — confirm with the nearest Chinese embassy or consulate before booking anything.
- Climate and cost of staying. A subtropical island with comparatively low living costs for a companion staying one to two weeks.
The United States: why BNCT is not an option there yet
As of 2026, there is no clinically available BNCT facility in the United States. In September 2025, TAE Life Sciences and the University of Wisconsin–Madison announced an agreement to install the country's first accelerator-based BNCT system (AlphaBeam) as a clinical trial site for head, neck and brain cancers. Until that programme is running and enrolling, BNCT is not something a US-based patient can obtain at home.
Two things are worth saying at the same time, because it is easy to read a statement like that as a sales pitch. First, the United States has exceptionally strong conventional treatment — surgery, chemoradiation, proton therapy — and for most patients with head and neck cancer, that is where treatment starts. Second, BNCT's approved indication is narrow: locally advanced or recurrent disease that cannot be operated on. It is not a general-purpose alternative to standard care, anywhere in the world.
For context on the financial question a US patient actually faces, published self-pay planning ranges for conventional re-treatment of head and neck cancer in the US are extremely wide — one widely cited planning table puts a proton therapy course for head and neck cancer at roughly US$120,000–180,000, while other sources quote US$100,000–150,000 or, for narrower package definitions, US$60,000–100,000. Intensity-modulated radiotherapy over 35 fractions is commonly estimated at US$25,000–40,000.
BNCT and photon or proton radiotherapy are different treatments with different indications; placing their prices side by side is not a like-for-like comparison, and we are not doing that here. The figures above are given only so that a US-based reader can gauge the order of magnitude of treatment locally. The right comparison is between options your treating physicians consider clinically appropriate for you — not between headline prices.
The costs that sit outside the treatment price
Whatever centre you approach, the headline treatment figure is only part of the budget. Ask any provider to confirm in writing which of the following are included:
- Pre-treatment imaging and assessment — PET/CT, MRI, pathology review, and above all the boron-uptake PET scan (FBPA-PET or 18F-BPA PET). This scan is not optional: if your tumour does not accumulate enough boron, you will not be treated.
- The boron drug itself, if it is billed separately and dosed by body weight.
- Inpatient stay and observation — typically several days to about a week.
- Travel and accommodation for you and, realistically, a companion, for one to two weeks.
- Interpretation and coordination, if not bundled.
- Follow-up imaging after you return home, which your local team will need to arrange.
- A second course, in cases where the team plans or later recommends repeat treatment.
Who is actually eligible
Eligibility for BNCT is narrower than most online discussions suggest. The approved indication is unresectable locally advanced or recurrent head and neck cancer. Centres generally also expect that the disease is localised rather than widely metastatic, that you can hold a consistent position for roughly 30 to 60 minutes, that the tumour's relationship to critical structures such as the carotid artery is workable, and that organ function is adequate.
Previous radiotherapy does not automatically disqualify you — re-irradiation is in fact one of the main reasons BNCT is considered — but it does require a cumulative dose assessment and a candid discussion of toxicity risk. Research programmes exist for glioma and melanoma in several countries, but those are investigational rather than approved indications.
The treating hospital's medical team decides eligibility, and only they decide it. OncoBridge does not assess medical suitability, does not influence that decision, and cannot guarantee that any patient will be accepted for treatment.
Frequently asked questions
Is BNCT covered by health insurance?
In Japan, national health insurance covers BNCT for approved head and neck indications for residents. In China it is currently self-pay and outside the national insurance scheme, although some commercial policies may cover part of the cost — check your own policy directly. For international patients travelling for treatment, it is almost always self-pay.
Why do quoted prices differ so much between sources?
Three reasons: some quotes cover treatment only while others are packages including accommodation, translation and transfers; the boron drug is dosed by body weight, so the drug component genuinely varies between patients; and some widely circulated figures are journalistic estimates rather than hospital quotations. Always ask for a written, itemised quotation from the treating centre.
Is BNCT in China the same as BNCT in Japan?
The Hainan centre uses the NeuCure® system and the boron-10 drug borofalan — the same platform used clinically in Japan. The same equipment does not mean the same experience, though: Japanese centres have been treating patients for years, while the Hainan programme started in early 2026 and its independently published outcome data remain limited.
How long does treatment take?
The neutron irradiation is typically a single session of about 30 to 60 minutes. Including pre-treatment assessment, boron-uptake PET imaging, drug infusion and observation, most patients should plan for roughly one to two weeks on site.
Can I get a price before travelling?
Yes, and you should insist on it. The standard pathway is to send your medical records and imaging for remote review first, with a quotation issued only after that review. A number quoted without it is not meaningful, because both eligibility and drug dose depend on your individual case.
Sources
- Sumitomo Heavy Industries / Stella Pharma — Japanese approval and reimbursement context for NeuCure® and borofalan, 2020 onwards.
- PW Consulting, Worldwide Boron Neutron Capture Therapy Market 2026 — bundled insurance payment of approximately JPY 2.7 million per approved head and neck course; installed-base and approval context.
- Southern Tohoku BNCT Research Center published rate structure (technology fee JPY 2.385m; drug fee JPY 444,000 per 18 kg), as reported in Chinese medical-travel and clinical literature.
- Tencent News / Medical World Think Tank, February 2026 — Panboron (Hainan) BNCT Hospital trial operation, Chinese approval scope, capacity, and cost modelling.
- Lecheng Medical / Bo'ao Lecheng pilot zone reporting — first BNCT treatment at the Hainan centre, March 2026, and treatment protocol description.
- CancerFax, Best BNCT Hospitals in China — centre-by-centre review of Chinese BNCT programmes, including the Hainan and Xiamen centres.
- Neutron Therapeutics / Helsinki University Hospital, 2025–2026 — Europe's first accelerator-based BNCT facility and its safety study.
- TAE Life Sciences / University of Wisconsin–Madison, September 2025 — announcement of the first US accelerator-based BNCT site.
- Published self-pay planning ranges for proton and intensity-modulated radiotherapy in the United States (multiple 2026 sources; ranges vary by methodology — see the caveat above).
This guide is published for general information and is not medical advice, a diagnosis, or a recommendation for any particular treatment or facility. Cost figures are indicative planning ranges compiled from the sources listed above, not quotations, and they change. BNCT is appropriate only for specific indications and only a treating medical team can determine eligibility. OncoBridge provides information and facilitation services; it does not provide medical care and does not guarantee any clinical outcome.